

Noah D Kauff

List of Publications by Citations

Source: <https://exaly.com/author-pdf/1073232/noah-d-kauff-publications-by-citations.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

90
papers

6,979
citations

35
h-index

83
g-index

95
ext. papers

7,802
ext. citations

7.1
avg, IF

5.12
L-index

#	Paper	IF	Citations
90	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. <i>New England Journal of Medicine</i> , 2002 , 346, 1609-15	59.2	1198
89	Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. <i>Journal of the National Cancer Institute</i> , 2009 , 101, 80-7	9.7	650
88	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1331-7	2.2	465
87	Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. <i>Journal of Clinical Oncology</i> , 2002 , 20, 1260-8	2.2	363
86	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. <i>JAMA - Journal of the American Medical Association</i> , 2015 , 313, 1347-61	27.4	286
85	Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. <i>Gynecologic Oncology</i> , 2007 , 107, 159-62	4.9	226
84	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. <i>PLoS Genetics</i> , 2013 , 9, e1003212	6	209
83	Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. <i>Lancet Oncology</i> , 2007 , 8, 26-34	21.7	186
82	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015 , 47, 164-71	36.3	177
81	American Society of Clinical Oncology Expert Statement: collection and use of a cancer family history for oncology providers. <i>Journal of Clinical Oncology</i> , 2014 , 32, 833-40	2.2	164
80	Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. <i>American Journal of Surgical Pathology</i> , 2009 , 33, 925-33	6.7	162
79	Uterine Cancer After Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations. <i>JAMA Oncology</i> , 2016 , 2, 1434-1440	13.4	151
78	Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. <i>Modern Pathology</i> , 2012 , 25, 625-36	9.8	150
77	BRCA mutations and risk of prostate cancer in Ashkenazi Jews. <i>Clinical Cancer Research</i> , 2004 , 10, 2918-21	21.9	139
76	Genome-wide association studies of cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 4255-67	2.2	127
75	Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2921-7	2.2	120
74	SGO White Paper on ovarian cancer: etiology, screening and surveillance. <i>Gynecologic Oncology</i> , 2010 , 119, 7-17	4.9	116

73	Early detection and prognosis of ovarian cancer using serum YKL-40. <i>Journal of Clinical Oncology</i> , 2004 , 22, 3330-9	2.2	112
72	Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. <i>American Journal of Surgical Pathology</i> , 2007 , 31, 744-51	6.7	108
71	Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations. <i>Clinical Cancer Research</i> , 2002 , 8, 3776-81	12.9	101
70	Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3275-83	2.2	94
69	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. <i>Genetics in Medicine</i> , 2019 , 21, 2390-2400	8.1	79
68	Epithelial lesions in prophylactic mastectomy specimens from women with BRCA mutations. <i>Cancer</i> , 2003 , 97, 1601-8	6.4	79
67	Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). <i>International Journal of Gynecological Cancer</i> , 2013 , 23, 1603-11	3.5	75
66	Survival in epithelial ovarian cancer: a multivariate analysis incorporating BRCA mutation status and platinum sensitivity. <i>Annals of Oncology</i> , 2011 , 22, 1127-1132	10.3	73
65	Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer. <i>Cancer</i> , 2012 , 118, 493-9	6.4	71
64	Risk of ovarian cancer in BRCA1 and BRCA2 mutation-negative hereditary breast cancer families. <i>Journal of the National Cancer Institute</i> , 2005 , 97, 1382-4	9.7	70
63	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2011 , 13, R110	8.3	62
62	Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. <i>Cancer</i> , 2012 , 118, 3703-9	6.4	61
61	Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. <i>Journal of the National Cancer Institute</i> , 2004 , 96, 68-70	9.7	59
60	Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 2311-3	4	51
59	The role of KRAS rs61764370 in invasive epithelial ovarian cancer: implications for clinical testing. <i>Clinical Cancer Research</i> , 2011 , 17, 3742-50	12.9	45
58	Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. <i>Breast Cancer Research and Treatment</i> , 2010 , 119, 409-14	4.4	43
57	Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status. <i>Cancer Prevention Research</i> , 2011 , 4, 1401-8	3.2	42
56	Risk of metachronous breast cancer after BRCA mutation-associated ovarian cancer. <i>Cancer</i> , 2013 , 119, 1344-8	6.4	37

55	Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. <i>Gynecologic Oncology</i> , 2003 , 89, 440-6	4.9	35
54	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. <i>PLoS Genetics</i> , 2014 , 10, e1004256	6	33
53	Genome-wide association studies of cancer predisposition. <i>Hematology/Oncology Clinics of North America</i> , 2010 , 24, 973-96	3.1	33
52	High-Grade Serous Ovarian Cancer: Associations between BRCA Mutation Status, CT Imaging Phenotypes, and Clinical Outcomes. <i>Radiology</i> , 2017 , 285, 472-481	20.5	31
51	Hereditary ovarian cancer in Ashkenazi Jews. <i>Familial Cancer</i> , 2004 , 3, 259-64	3	31
50	Invasion patterns of metastatic high-grade serous carcinoma of ovary or fallopian tube associated with BRCA deficiency. <i>Modern Pathology</i> , 2014 , 27, 1405-11	9.8	30
49	Treatment of infertility does not increase the risk of ovarian cancer among women with a BRCA1 or BRCA2 mutation. <i>Fertility and Sterility</i> , 2016 , 105, 781-785	4.8	28
48	The TP53 mutational spectrum and frequency of CHEK2*1100delC in Li-Fraumeni-like kindreds. <i>Familial Cancer</i> , 2005 , 4, 177-81	3	28
47	Is It time to stratify for BRCA mutation status in therapeutic trials in ovarian cancer?. <i>Journal of Clinical Oncology</i> , 2008 , 26, 9-10	2.2	27
46	Reducing the risk of gynecologic cancer in the Lynch syndrome. <i>New England Journal of Medicine</i> , 2006 , 354, 293-5	59.2	27
45	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. <i>PLoS ONE</i> , 2015 , 10, e0120020	3.7	26
44	BRCA mutations in women with ductal carcinoma in situ. <i>Clinical Cancer Research</i> , 2007 , 13, 4306-10	12.9	26
43	Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma. <i>Gynecologic Oncology</i> , 2012 , 126, 224-8	4.9	25
42	RE: Breast Cancer Risk After Salpingo-Oophorectomy in Healthy BRCA1/2 Mutation Carriers: Revisiting the Evidence for Risk Reduction. <i>Journal of the National Cancer Institute</i> , 2015 , 107,	9.7	23
41	Ovarian carcinoma screening in women at intermediate risk: impact on quality of life and need for invasive follow-up. <i>Cancer</i> , 2005 , 104, 314-20	6.4	23
40	SpinThin, a simple, inexpensive technique for preparation of thin-layer cervical cytology from liquid-based specimens. <i>Cancer</i> , 2000 , 90, 135-142	6.4	23
39	Rare de novo germline copy-number variation in testicular cancer. <i>American Journal of Human Genetics</i> , 2012 , 91, 379-83	11	20
38	Incorporating information regarding preimplantation genetic diagnosis into discussions concerning testing and risk management for BRCA1/2 mutations: a qualitative study of patient preferences. <i>Cancer</i> , 2012 , 118, 6270-7	6.4	20

37	Invasion Patterns of Metastatic Extrauterine High-grade Serous Carcinoma With BRCA Germline Mutation and Correlation With Clinical Outcomes. <i>American Journal of Surgical Pathology</i> , 2016 , 40, 404-9	6.7	19
36	Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?. <i>Gynecologic Oncology</i> , 2004 , 93, 277-9	4.9	18
35	Estrogen receptor-beta expression in hereditary breast cancer. <i>Journal of Clinical Oncology</i> , 2002 , 20, 3752-3; author reply 3753	2.2	18
34	Hereditary ovarian cancer: recent molecular insights and their impact on screening strategies. <i>Current Opinion in Oncology</i> , 2011 , 23, 526-30	4.2	16
33	How should women with early-onset endometrial cancer be evaluated for lynch syndrome?. <i>Journal of Clinical Oncology</i> , 2007 , 25, 5143-6	2.2	16
32	Insurance reimbursement for risk-reducing mastectomy and oophorectomy in women with BRCA1 or BRCA2 mutations. <i>Genetics in Medicine</i> , 2001 , 3, 422-5	8.1	16
31	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016 , 141, 386-401	4.9	15
30	Discriminatory accuracy and potential clinical utility of genomic profiling for breast cancer risk in BRCA-negative women. <i>Breast Cancer Research and Treatment</i> , 2011 , 127, 479-87	4.4	15
29	Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2010 , 123, 581-5	4.4	15
28	Screening and prevention of hereditary gynecologic cancers. <i>Seminars in Oncology</i> , 2007 , 34, 406-10	5.5	15
27	Intractable bleeding managed with Foley catheter tamponade after dilation and evacuation. <i>American Journal of Obstetrics and Gynecology</i> , 1995 , 173, 957-8	6.4	14
26	Accuracy of BRCA1 and BRCA2 founder mutation analysis in formalin-fixed and paraffin-embedded (FFPE) tissue. <i>Familial Cancer</i> , 2006 , 5, 337-42	3	13
25	Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3116-3123	3.1	12
24	Development and validation of a clinical score for predicting risk of adenoma at screening colonoscopy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015 , 24, 913-20	4	12
23	Tamoxifen and the risk of ovarian cancer in BRCA1 mutation carriers. <i>Gynecologic Oncology</i> , 2009 , 115, 135-137	4.9	12
22	Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. <i>Gynecologic Oncology</i> , 2011 , 123, 196-9	4.9	10
21	The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy. <i>Gynecologic Oncology</i> , 2006 , 102, 315-8	4.9	8
20	Assessment of individuals with BRCA1 and BRCA2 large rearrangements in high-risk breast and ovarian cancer families. <i>Breast Cancer Research and Treatment</i> , 2014 , 145, 625-34	4.4	7

19	Assessment of the prevalence of de novo mutations in the BRCA1 and BRCA2 genes. <i>Clinical Genetics</i> , 2011 , 80, 97-8	4	7
18	Modeling genetic risk of breast cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007 , 297, 2637-9	27.4	7
17	Laparoscopic bilateral salpingo-oophorectomy in breast cancer patients after transverse rectus abdominus myocutaneous flap reconstructive surgery. <i>Gynecologic Oncology</i> , 2005 , 99, 720-5	4.9	7
16	Risk-Reducing Salpingo-Oophorectomy and Breast Cancer Risk Reduction in the Gynecologic Oncology Group Protocol-0199 (GOG-0199). <i>JNCI Cancer Spectrum</i> , 2020 , 4, pkz075	4.6	7
15	Genome Sequencing of Multiple Primary Tumors Reveals a Novel PALB2 Variant. <i>Journal of Clinical Oncology</i> , 2016 , 34, e61-7	2.2	6
14	Adenoma Prevalence in Blacks and Whites Having Equal Adherence To Screening Colonoscopy: The National Colonoscopy Study. <i>Clinical Gastroenterology and Hepatology</i> , 2017 , 15, 1469-1470	6.9	4
13	Weighing options for cancer risk reduction in carriers of BRCA1 and BRCA2 mutations. <i>Journal of Clinical Oncology</i> , 2010 , 28, 189-91	2.2	4
12	Prophylactic oophorectomy may differentially reduce breast cancer risk in women with BRCA1 versus BRCA2 mutations. <i>Current Breast Cancer Reports</i> , 2009 , 1, 157-161	0.8	4
11	Breast cancer: oophorectomy for BRCA1 ER--negative disease-an open debate. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 505-6	19.4	3
10	Risk-Reducing Salpingo-Oophorectomy in Women With a BRCA1 or BRCA2 Mutation. <i>Obstetrical and Gynecological Survey</i> , 2002 , 57, 574-575	2.4	3
9	Prospective follow-up of quality of life for participants undergoing risk-reducing salpingo-oophorectomy or ovarian cancer screening in GOG-0199: An NRG Oncology/GOG study. <i>Gynecologic Oncology</i> , 2020 , 156, 131-139	4.9	2
8	Universal screening for Lynch syndrome in uterine cancer patients: A quality improvement initiative. <i>Gynecologic Oncology</i> , 2021 , 160, 169-174	4.9	2
7	Reservations About Risk-Reducing Salpingo-oophorectomy Without Hysterectomy in Women With BRCA Mutations-Reply. <i>JAMA Oncology</i> , 2017 , 3, 417-418	13.4	1
6	Disease genes and chromosomes: disease maps of the human genome.Chromosome 12. <i>Genetic Testing and Molecular Biomarkers</i> , 2000 , 4, 319-33		1
5	Management of high, moderate, and low penetrance ovarian cancer susceptibility mutations: an assessment of current risk reduction practices. <i>International Journal of Gynecological Cancer</i> , 2020 , 30, 1583-1588	3.5	1
4	Trauma in the obstetric patient: Evaluation and management. <i>Primary Care Update for Ob/Gyns</i> , 1998 , 5, 16-20		0
3	Cancer of the Ovary 2010 , 1052-1066		0
2	Risk-Reducing Salpingo-Oophorectomy for the Prevention of Inherited Breast and Ovarian Cancer 2008 , 79-91		

- 1 Management of BRCA Mutation-Negative Patients **2008**, 107-115